Pipeline

Aduro’s extensive pipeline of diverse product candidates builds from proprietary technologies (STING Pathway Activators and B-select monoclonal antibodies) to create immunotherapies targeting a variety of cancers, as well as infectious and autoimmune diseases.

STING Pathway Programs

ADU-S100

Multiple tumors
 
     

ADU-S100

Multiple tumors
antiPD-1
     

Adjuvant

Infectious Disease
 
     

STING-Blok

Autoimmune Disease
 
     
Indication
Combination

B-select Programs

Anti-APRIL

Multiple Myeloma
 
     

Anti-CD27 agonist

Oncology
 
     

Anti-CTLA4

Oncology
 
     

Bispecific Ab

Oncology
 
     
Indication
Combination

Personalized LADD Program

pLADD

MSS Colorectal
 
     
Indication
Combination